Timothy E. Byun, MD | Orange, CA

Dr. Timothy E. Byun

Claim this profile

Saint Joseph Hospital - Orange

Studies Lung Cancer
Studies Breast cancer
30 reported clinical trials
84 drugs studied

About Timothy E. Byun

Education:

  • Earned his MD from the University of California, Irvine School of Medicine.
  • Completed residency in Internal Medicine at the University of California, Irvine Medical Center.
  • Undertook a fellowship in Hematology and Oncology at the City of Hope National Medical Center.

Experience:

  • Specializes in Hematology and Oncology at Saint Joseph Hospital - Orange.

Area of expertise

1Lung Cancer
Timothy E. Byun has run 9 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Timothy E. Byun has run 7 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
ER positive
ER negative

Affiliated Hospitals

Image of trial facility.
Saint Joseph Hospital - Orange
Image of trial facility.
St. Joseph Hospital, The Center For Cancer Prevention And Treatment, Providence

Clinical Trials Timothy E. Byun is currently running

Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Timothy E. Byun

Clinical Trial Related8 years of experience running clinical trials · Led 30 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Timothy E. Byun has experience with
  • Pembrolizumab
  • Oxaliplatin
  • Paclitaxel
  • Fluorouracil
  • Nivolumab
  • Ipatasertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Timothy E. Byun specialize in?
Is Timothy E. Byun currently recruiting for clinical trials?
Are there any treatments that Timothy E. Byun has studied deeply?
What is the best way to schedule an appointment with Timothy E. Byun?
What is the office address of Timothy E. Byun?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security